Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s latest US patent allowance, progress within its PTSD drug development program, and what investors should expect during a potentially catalyst-rich 2026.
Tennyson explained that the newly allowed US patent for the SVN-SDN-14 program represents a significant step in building long-term value. He said the patent provides “composition of matter protection over a new chemical series within our PTSD program,” strengthening the intellectual property foundation as the company approaches lead candidate selection. According to Tennyson, this protection improves the commercial quality of the asset while extending its future value window, without altering near-term development timelines.
The CEO outlined the company’s focus on treating post-traumatic stress disorder, noting it affects around 13 million people across the major pharmaceutical markets and currently lacks a specifically licensed medicine. Solvonis Therapeutics PLC is pursuing a differentiated approach, concentrating on mechanisms that support therapeutic engagement through pro-social neurochemistry rather than symptom suppression alone.
Looking ahead to Q1 2026, Tennyson highlighted the milestones investors should monitor, including completion of in-vivo work, confirmation of brain activity, narrowing the candidate set, and final lead selection. He described this as “a key inflection point as the program transitions from discovery to IND enabling work.”
Beyond PTSD, Tennyson discussed broader pipeline progress across addiction and psychiatric indications.
He said 2026 could be a catalyst-rich year, with advancement of clinical programs, potential partnering discussions, and continued progress within the company’s discovery engine.
For more interviews like this, visit Proactive’s YouTube channel, give the video a like, subscribe, and enable notifications so you never miss future updates.
#SolvonisTherapeutics #SVNS #BiotechStocks #DrugDevelopment #PTSDResearch #MentalHealthBiotech #AddictionTreatment #ClinicalTrials #Biopharma #HealthcareInvesting #LSEStocks #PatentNews
